Cell-based assay panel for oncology. Industry experience in laboratory automation.
Elucidation of compound binding mode and mechanism of action. Binding kinetics.
Chemical biology of new drug targets. Integrated design and synthesis of new chemical entities. Focus on excellent ADME properties.
Synergy testing of candidate molecules (SynergyFinder) is combined with classic and modern therapeutic agents on a broad panel of tumor cell lines.
Novel leads and preclinical candidates for innovative targets from academia.
"We bridge the innovation gap by translating academic science into novel medicines."Guido ZamanNTRC translates novel ideas for the treatment of human disease into small molecule drug candidates. Our expertise includes cell-based and biochemical assay development, high-throughput screening, protein x-ray crystallography, and medicinal chemistry. We collaborate with world-class academic centers on drugable targets in oncology, autoimmune disease and neurodegenerative disease.
"Our drug discovery capabilities are available as a fee-for-service to fulfill your project needs."Suzanne van GerwenOur breakthrough technology platforms are available as NTRC Services. We provide these services according to the highest standards in pharmaceutical industry. Our services include:
"Our pharma background allows us to perform drug discovery at the highest industrial standard"Rogier Buijsman
NTRC's drug discovery projects are available to pharmaceutical companies for in-licensing. We have projects on innovative targets in:Oncology